Is type 2 diabetes mellitus a vascular condition?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 10, 2003, Pages 1715-1716

  Hu, Frank B ^a   Stampfer, Meir J ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; METFORMIN; PADGEM PROTEIN; STATINE DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; ENDOTHELIUM CELL; EPIDEMIOLOGICAL DATA; FOLLOW UP; GLUCOSE INTOLERANCE; HEREDITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTERNAL CAROTID ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ARTERIOSCLEROSIS; CAROTID ARTERY, COMMON; DIABETES MELLITUS, TYPE 2; HUMANS; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 0141954218     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000094360.38911.71     Document Type: Editorial

References (31)

1. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA. 1990;263: 2893-2898.
2. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
3. Stern MP. Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes. 1995;44:369-374.
4. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343:16-22.
5. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-797.
6. Rich-Edwards JW, Stampfer MJ, Manson JE, Rosner B, Hankinson SE, Colditz GA, Willett WC, Hennekens CH. Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. BMJ. 1997;315:396-400.
7. The Diabetes Prevention Program Research Group. The effects of intensive lifestyle intervention (ILS) and metformin (MET) on the incidence of metabolic syndrome among participants in the Diabetes Prevention Program (DPP). Diabetes. 2003;52:A58. Abstract.
8. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001; 103:357-362.
9. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
10. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291-1296.
11. Hunt KJ, Williams K, Rivera D, O'Leary DH, Haffner SM, Stern MP, Gonzales Villalpando C. Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23:1845-1850.
12. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46(Suppl 2):S9-S13.
13. Cooke JP. The endothelium: a new target for therapy. Vasc Med. 2000;5:49-53.
14. Vane JR, Bom GVR, Welzel D. The Endothelial Cell in Health and Disease. Stuttgart, Germany: Schattauer; 1995.
15. Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A, Gonano F, Bartoli E. Increased circulating intercellular adhesion molecule-1 levels in type II diabetic patients: the possible role of metabolic control and oxidative stress. Metabolism. 1996;45:498-501.
16. Cominacini L, Pasini AF, Garbin U, Davoli A, De Santis A, Campagnola M, Rigoni A, Zenti MG, Moghetti P, Lo Cascio V. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia. 1995;38:1122-1124.
17. Hackman A, Abe Y, Insull WJ, Pownall H, Smith L, Dunn K, Gotto AMJ, Ballantyne CM. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996;93:1334-1338.
18. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
19. Hwang S-J, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AMJ, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96: 4219-4225.
20. Meigs JB, Hu FB, Manson JE. Endothelial dysfunction predicts development of type 2 diabetes. Diabetes. 2003;52:A58. Abstract.
21. Meigs JB, D'Agostino RB Sr, Nathan DM, Rifai N, Wilson PW. Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care. 2002;25:977-983.
22. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
23. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282: 2131-2135.
24. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
25. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol. 2003;23:650-655.
26. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286: 327-334.
27. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50: 2384-2389.
28. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596-600.
29. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52: 812-817.
30. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation [published erratum appears in N Engl J Med 1999;340:1376]. N Engl J Med. 1999;340:448-454.
31. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation [published erratum appears in N Engl J Med 1999;340:1376]. N Engl J Med. 1999;340:448-454.